Article
Crown jewel in big Gilead buyout lands breakthrough designation for MDS
Rating:
0.0
Views:
111
Likes:
1
Library:
1
Months after Gilead snagged magrolimab in the $4.9 billion buyout of California biotech Forty Seven — the company's largest acquisition in three years at the time — the anti-CD47 monoclonal antibody is now on an expedited track to approval. On Tuesday morning, Gilead announced magrolimab's FDA breakthrough therapy designation for
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value